• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BSHRI discovers new evidence in Alzheimer’s disease research

BSHRI discovers new evidence in Alzheimer’s disease research

May 13, 2011
CenterWatch Staff

Researchers at Banner Sun Health Research Institute (BSHRI) have found further evidence linking copper to the increased probability of developing Alzheimer's disease, according to a recent study published in the International Journal of Alzheimer's Disease. 

The study, led by BSHRI researcher Dr. Larry Sparks, employed a cholesterol-fed model of Alzheimer's disease to investigate the relationship between Alzheimer's disease-like neurofibrillary tangle (NFT) neuropathology and tau protein levels as the main component of NFT.

Researchers measured brain and plasma tau levels and semi-quantified NFT-like neuropathology in cholesterol-fed rabbits administered drinking water of varying quality (distilled, tap and distilled with copper) compared to animals receiving normal food and local tap water.

"Total tau levels in plasma were increased in all cholesterol-fed rabbits compared to animals on normal chow, regardless of quality of water," said Sparks. "These studies suggest the possibility that circulating tau could be the source of the tau accumulating in the brain."

Previously, copper has been implicated in the progression and possibly the cause of Alzheimer's disease as studies have shown the that increased copper intake significantly increases the rate of progression of Alzheimer's disease in the setting of elevated fat intake.

In the BSHRI study, Sparks and his team performed a pilot study of long-term dietary cholesterol in four groups of rabbits. One group was administered normal food and water and three groups were administered increasing levels of a cholesterol diet for five months. Significantly, plasma levels of tau increased by 40 to 50 percent in each of the cholesterol-fed animal groups after five months of the experimental diet.

"This is the first study of the effect of intake of copper or trace metals on levels of the protein tau in the blood and brain," Sparks added. "We have shown that there is increased tau neuropathology associated with increasing levels of tau in the blood and brain of the cholesterol-fed rabbit."

 

 

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing